Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
- New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025
- Upfront payments of USD 2 million
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, October 19, 2023
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with privately owned Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.
David Veitch, Chief Executive Officer of Basilea, stated: “This is the first transaction in the implementation of our strategy to expand our clinical-stage anti-infectives pipeline and to complement our portfolio of marketed products, Cresemba and Zevtera. We are looking forward to developing this asset.”
Dr. Marc Engelhardt, Chief Medical Officer of Basilea, added: “With GR-2397, now referred to as BAL2062, we are adding an antifungal compound to our pipeline that has already completed a clinical phase 1 study. Based on its novel mechanism of action which results in rapid fungicidal activity in vitro, BAL2062 could become a valuable treatment option against difficult-to-treat invasive mold infections. To define the optimal positioning and the most efficient clinical development path, we will initiate a focused preclinical profiling program. Upon successful completion of the preclinical profiling, we are planning to move directly into phase 2 clinical development in the first half of 2025.”
BAL2062 (formerly GR-2397) is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.1 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.2 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food & Drug Administration (FDA) for invasive aspergillosis.
Basilea is paying USD 2 million in upfront payments. Under the asset purchase agreement with Gravitas, Basilea assumes the rights and obligations under a license agreement with Astellas Pharma Inc. who owns patents relating to BAL2062 (formerly GR-2397) and takes over an agreement with Fresh Tracks Therapeutics Inc., who previously owned the asset that was acquired by Gravitas. Upon achievement of defined milestones, Basilea will make total pre-approval milestone payments of up to USD 1.75 million and up to USD 67 million in total approval and commercialization milestone payments. In addition, Basilea will pay tiered royalties on sales starting in the low single-digit percentage range, going to the mid-single-digit percentage range.
About invasive aspergillosis
Invasive aspergillosis is a life-threatening mold infection that predominantly affects immunocompromised patients, such as patients with hematologic malignancies (blood cancer). The infection is associated with high morbidity and mortality.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have an R&D portfolio of anti-infective assets. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
|Phone||+41 61 606 1102|
This ad hoc announcement can be downloaded from www.basilea.com.
- K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909
- ClinicalTrials.gov identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Constellation Brands to Report Third Quarter Fiscal 2024 Financial Results; Host Conference Call January 5, 202430.11.2023 22:30:18 CET | Press release
VICTOR, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its third quarter ended November 30, 2023, on Friday, January 5, 2024, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Financial Officer, Garth Hankinson, at 10:30 a.m. ET, January 5, 2024. The conference call can be accessed by dialing +1-877-407-9121 and entering conference identification number 13742927, beginning at 10:20 a.m. ET. A live, listen-only webcast of the conference call will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the call begins, financial information discussed on the conference call, and reconciliations of reported GAAP financial measures with comparable and other
Fluence Named an Official UN Global Compact Signatory Member30.11.2023 22:30:00 CET | Press release
Fluence’s participation as a signatory member of the UN Global Compact is well ahead of the 2024-2025 expected timeline outlined in the Company’s 2022 Sustainability Report ARLINGTON, Va., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a leading global provider of energy storage products and services, and optimization software for renewables and storage, announced today that Fluence has been accepted as an official United Nations Global Compact signatory member, well ahead of the 2024-2025 timeline outlined in Fluence’s 2022 Sustainability Report. The UN Global Compact is the world's largest corporate sustainability initiative, calling on companies to align their operations and strategies with the Ten Principles of the UN Global Compact in the areas of human rights, labor, environment, and anti-corruption. By becoming a signatory, Fluence reinforces its commitment to these principles and the broader goals of sustainable development and aims to streng
Atlantic Petroleum – Condensed Consolidated Interim Report – 3rd Quarter 202330.11.2023 22:11:49 CET | Press release
Tórshavn, Faroe Islands, 2023-11-30 (GLOBE NEWSWIRE) -- P/F Atlantic Petroleum (NASDAQ Copenhagen: ATLA DKK) today posts its 3rd quarter results for 2023. This announcement should be read in conjunction with Atlantic Petroleum’s Condensed Consolidated Interim Report, which is released separately and posted on the Company’s website. Highlights for Q3 2023: G&A cost was DKK 2.0MM Operating loss was DKK 0.0MM Net loss was DKK 1.5MM Net assets/share-holders equity was DKK -98.8MM Bank debt was DKK 59.4MM Atlantic Petroleum in brief: Atlantic Petroleum participates in oil and gas joint ventures with reputable, international partners. Atlantic Petroleum P/F is based in Tórshavn, Faroe Islands, and the Company currently has subsidiaries and offices in the UK. Atlantic Petroleum’s shares are listed on NASDAQ OMX Copenhagen. Further Details: Further details can be obtained from Mark T. Højgaard, (email@example.com). This announcement will be available, together with other information about Atl
Amlan® International Expands in Southern Vietnam with New Distribution Partner, Saigon Nutrition Corporation30.11.2023 22:00:00 CET | Press release
CHICAGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America (NYSE: ODC) and a global leader in mineral-based feed additives that optimize the intestinal health of poultry and livestock, is pleased to announce an expansion of their presence in the Southern Vietnam market through a new distribution partnership with Saigon Nutrition Corporation. Amlan entered into a distributor agreement with Saigon Nutrition effective September 30th, 2023. As a trusted brand in the animal health industry, Amlan is committed to bringing natural and effective feed additives to enhance animal health and productivity. Saigon Nutrition, which is well established and respected in the region, will manage the distribution of Amlan products for the Southern Region of Vietnam. This partnership will allow for better alignment of customer needs and industry demands. Saigon Nutrition is now authorized to distribute Calibrin®-Z, Varium®, Calibrin®-A, N
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer30.11.2023 21:00:00 CET | pressemeddelelse
KØBENHAVN, Danmark, 30. november 2023 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnHenrik Juuel2.Årsag til indberetningena)Stilling/titelExecutive Vice President og Chief Financial Officer i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen Ident